-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Initiates Coverage On Inhibikase Therapeutics with Outperform Rating, Announces Price Target of $5

Benzinga·06/10/2026 18:02:56
Listen to the news
Oppenheimer initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Outperform rating and announces Price Target of $5.